Effect of Achieved Systolic Blood Pressure on Cardiovascular Outcomes in Patients With Type 2 Diabetes: A Population-Based Retrospective Cohort Study
- 28 March 2018
- journal article
- research article
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (6) , 1134-1141
Abstract
OBJECTIVE: The objective of this study was to compare the incidence of cardiovascular disease (CVD) among patients with type 2 diabetes mellitus (T2DM) with treated hypertension who achieved systolic blood pressures (SBPs) of <120, <130, and <140 mmHg after an increase in their antihypertensive regimen. RESEARCH DESIGN AND METHODS: A retrospective cohort study was conducted on 28,014 primary care adult patients with T2DM with no prior diagnosis of CVD and who achieved SBP readings <140 mmHg after an increase in the number of antihypertensive medications prescribed. Using an extension of propensity score matching, a total of 2,079, 10,851, and 15,084 matched patients with achieved SBP measurements of <120, <130, and <140 mmHg were identified. The association between achieved SBP and incident CVD were evaluated using Cox regressions. Subgroup analyses were conducted by stratifying patients’ baseline characteristics. RESULTS: Over a median follow-up period of 4.8 years, the incidence of CVD in patients with achieved SBP measures of <120, <130, and <140 mmHg were 318 (15.3%; incidence rate [IR] 34.3/1,000 person-years [PY]), 992 (9.1%; IR 20.4/1,000 PY), and 1,635 (10.8%; IR 21.4/1,000 PY). Achieved SBP <120 mmHg was associated with a higher risk of CVD compared with achieved SBP <130 mmHg (hazard ratio [HR] 1.75 [95% CI 1.53, 2.00]) and achieved SBP <140 mmHg (HR 1.67 [95% CI 1.46, 1.90]). There was a significant reduction in CVD risk in patients <65 years (HR 0.81 [95% CI 0.69, 0.96]) but no difference for other patients, including patients ≥65 years, who achieved SBP <130 mmHg when compared with the group that achieved SBP <140 mmHg. CONCLUSIONS: Our findings support a SBP treatment target of 140 mmHg and suspect no risk reduction attenuation on CVD for lower SBP targets (<120 or <130 mmHg) for most patients with uncomplicated T2DM. A randomized control trial is still needed to confirm these findings.Keywords
Funding Information
- Food and Health Bureau (EPC-HKU-2)
This publication has 51 references indexed in Scilit:
- Observational Studies Versus Randomized Controlled Trials: Avenues to Causal Inference in NephrologyAdvances in Chronic Kidney Disease, 2012
- Cardiovascular Outcomes in Framingham Participants With DiabetesHypertension, 2011
- Marginal Mean Weighting Through Stratification: Adjustment for Selection Bias in Multilevel DataJournal of Educational and Behavioral Statistics, 2010
- Blood pressure targets: are clinical guidelines wrong?Current Opinion in Cardiology, 2010
- Effects of Intensive Blood-Pressure Control in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Health services research in the public healthcare system in Hong Kong: An analysis of over 1 million antihypertensive prescriptions between 2004–2007 as an example of the potential and pitfalls of using routinely collected electronic patient dataBMC Health Services Research, 2008
- Using the outcome for imputation of missing predictor values was preferredJournal of Clinical Epidemiology, 2006
- Evidence of a Dominant Backward-Propagating “Suction” Wave Responsible for Diastolic Coronary Filling in Humans, Attenuated in Left Ventricular HypertrophyCirculation, 2006
- Mechanisms, Pathophysiology, and Therapy of Arterial StiffnessArteriosclerosis, Thrombosis, and Vascular Biology, 2005
- Developing a prognostic model in the presence of missing dataJournal of Clinical Epidemiology, 2003